Meeting
2017 ASCO Annual Meeting
Blood measurements of neuroendocrine tumor (NET) transcripts and gene cluster analysis to predict efficacy of peptide radioreceptor therapy.
Authors
Lisa Bodei
Memorial Sloan Kettering Cancer Center, New York, NY
Lisa Bodei , Mark S. Kidd , Wouter A van der Zwan , Ignat Drozdov , Richard P. Baum , Dik J. Kwekkeboom , Eric Krenning , Irvin Mark Modlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4091)
DOI
10.1200/JCO.2017.35.15_suppl.4091
Abstract #
4091
Poster Bd #
83
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Circulating neuroendocrine transcripts and gene cluster analysis to predict the efficacy of peptide radioreceptor therapy.
First Author: Lisa Bodei
Poster
2018 ASCO Annual Meeting
Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.
First Author: Lisa Bodei
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.
First Author: Thorvardur Ragnar Halfdanarson